Spravato (esketamine)

news

FDA approves innovative monotherapy for treatment-resistant depression

22 January 2025 | By Catherine Eckford (European Pharmaceutical Review)

J&J’s standalone small molecule drug was approved based on evidence of improvement of depressive symptoms without the need for patients to take a daily oral antidepressant.

news

ECNP 2023: new esketamine NS safety data for depression

10 October 2023 | By Catherine Eckford (European Pharmaceutical Review)

New safety data for a Phase IIIb study in treatment-resistant depression (TRD), revealed at ECNC 2023, showed that esketamine NS significantly increased the proportion of patients achieving remission compared to quetiapine XR.

news

Nasal spray for depression shows long-term efficacy

27 March 2023 | By Catherine Eckford (European Pharmaceutical Review)

SPRAVATO® achieved significant long-term response rates in treatment-resistant depression, compared to quetiapine extended release, Janssen’s Phase IIIb study has shown.

news

Nasal spray could help prevent depression relapse

28 November 2022 | By Catherine Eckford (European Pharmaceutical Review)

SPRAVATO® nasal spray helped treatment-resistant depression patients remain remission and relapse free in a Phase III trial.

article

Why it’s high time for psychedelic drug development

25 May 2021 | By Hannah Balfour (European Pharmaceutical Review)

Here, Dr Matthew McMurray and Dr J Andrew Jones of Miami University explain why psychedelic drugs are attracting R&D as potential treatments for neuropsychiatric and degenerative disorders and how their discovery of an in vivo production technique could enable further advancement.

article

How can we develop more effective antidepressants?

4 May 2020 | By Victoria Rees (European Pharmaceutical Review)

Sergio Traversa, PharmD, from Relmada Therapeutics explains why NMDA antagonists may provide an answer for patients who do not respond to current antidepressant therapies.

news

NICE does not recommend esketamine for treatment-resistant depression

31 January 2020 | By Hannah Balfour (European Pharmaceutical Review)

Esketamine nasal spray did not receive a positive opinion from NICE due to inadequate comparisons to other therapies and concerns over its cost effectiveness.

news

Regulatory expansion submitted for SPRAVATO^® (esketamine) nasal spray

20 January 2020 | By Hannah Balfour (European Pharmaceutical Review)

Janssen have applied to the EMA to extend the use of esketamine to a short-term treatment for the rapid reduction of depressive symptoms in adults with MDD who are suicidal with the intent.

news

Seven medicines recommended for approval by EMA

21 October 2019 | By Victoria Rees (European Pharmaceutical Review)

The EMA CHMP has given a positive opinion for marketing authorisation approval to seven medicines following its October meeting.